文献速递白血病

ELTS评分较Sokal评分更准确预测CML患者TKI治疗反应与结局

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
PubMed 文献 · Leukemia · 2021-08-19

该研究纳入1661例连续慢性期CML患者,初始接受伊马替尼(n=1379)或二代TKI(n=282),比较Sokal与ELTS评分对治疗反应和结局的预测准确性。两种评分均能预测所有患者及伊马替尼治疗患者的CCyR、MMR、FFS、PFS和生存概率,但ELTS评分对MR4、MR4.5和CML相关生存的预测优于Sokal评分。在二代TKI治疗患者中,仅ELTS评分能准确预测CCyR、MMR、MR4、FFS和PFS。倾向性评分匹配显示,ELTS评分为中危的患者接受二代TKI治疗在反应(p<0.001~0.061)、FFS(p=0.002)和PFS(p=0.03)方面更优,但生存无差异。

要点

  • ELTS评分对CML患者治疗反应和结局的总体预测准确性优于Sokal评分。
  • 在二代TKI治疗患者中,仅ELTS评分能准确预测CCyR、MMR、MR4、FFS和PFS。
  • ELTS中危患者接受二代TKI治疗可能获得更好的替代终点,但生存无差异。

核心结论

  • 在CML患者中,ELTS评分较Sokal评分具有更好的总体预测准确性,尤其在接受二代TKI治疗的患者中。

研究设计与样本

  • 研究纳入1661例连续慢性期CML患者,初始接受伊马替尼(n=1379)或二代TKI(n=282),比较Sokal与ELTS评分的预测准确性。

主要发现

  • 两种评分均能预测所有患者及伊马替尼治疗患者的CCyR、MMR、FFS、PFS和生存概率。
  • ELTS评分对MR4、MR4.5和CML相关生存的预测优于Sokal评分。
  • 在二代TKI治疗患者中,仅ELTS评分能准确预测CCyR、MMR、MR4、FFS和PFS。
  • 倾向性评分匹配显示,ELTS中危患者接受二代TKI治疗在反应(p<0.001~0.061)、FFS(p=0.002)和PFS(p=0.03)方面更优,但生存无差异。

临床怎么用

  • 在CML患者初始治疗选择中,可优先使用ELTS评分进行风险分层和预后预测。
  • 对于ELTS评分中危且以更快达到停药目标为治疗目的的患者,可考虑初始二代TKI治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data from 1661 consecutive subjects with chronic-phase chronic myeloid leukemia (CML) receiving initial imatinib (n = 1379) or a 2nd-generation tyrosine-kinase inhibitor (2G-TKI; n = 282) were interrogated to determine whether the Sokal or European Treatment and Outcome Study for CML (EUTOS) long-term survival (ELTS) scores were more accurate responses and outcome predictors. Both scores predicted probabilities of achieving complete cytogenetic response (CCyR), major molecular response (MMR), failure- and progression-free survivals (FFS, PFS), and survival in all subjects and those receiving imatinib therapy. However, the ELTS score was a better predictor of MR4, MR4.5, and CML-related survival than the Sokal score. In subjects receiving 2G-TKI therapy, only the ELTS score accurately predicted probabilities of CCyR, MMR, MR4, FFS, and PFS. In the propensity score matching, subjects classified as intermediate risk by the ELTS score receiving a 2G-TKI had better responses (p < 0.001~0.061), FFS (p = 0.002), and PFS (p = 0.03) but not survival. Our data suggest better overall prediction accuracy for the ELTS score compared with the Sokal score in CML patients, especially those receiving 2G-TKIs. People identified as intermediate risk by the ELTS score may benefit more from initial 2G-TKI therapy in achieving surrogate endpoints but not survival, especially when a briefer interval to stopping TKI therapy is the therapy objective.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang XS, Gale RP, Huang XJ, et al. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2021. PMID: 34413457. doi:10.1038/s41375-021-01387-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。